Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Background Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no
approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor beta …

Background Lipoprotein (a) is a presumed risk factor for atherosclerotic cardiovascular
disease. Olpasiran is a small interfering RNA that reduces lipoprotein (a) synthesis in the …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

Background Mediterranean and low-fat diets are effective in the primary prevention of
cardiovascular disease. We did a long-term randomised trial to compare the effects of these …

These guidelines will be updated every four years. Vascular centres are encouraged to audit
implementations made as a result of the guidelines. Audit cycles should be repeated and …

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved
treatment. MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo …